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Objective: Febrile neutropenia is a major complication in patients with malignancies receiving chemo-
therapy. The pathogens vary in different geographic areas, however, and also may vary in different
institutions. This retrospective study analyzed the proﬁle of bacteria in cases of febrile neutropenia at
a single medical center in eastern Taiwan.
Materials and Methods: From July 2006 to July 2007, we retrospectively evaluated 80 adult cancer
patients who were admitted to the hematology and oncology ward in our hospital because of febrile
neutropenia. The clinical characteristics of those who survived (survival group) and those who died
(mortality group) were compared. The blood culture data and susceptibility to antibiotics during
episodes of febrile neutropenia were obtained for interpretation.
Results: Among a total of 110 episodes of febrile neutropenia, 31% had documented bacteremia. The most
common malignancy among these patients was acute leukemia (31%), followed by non-Hodgkin’s
lymphoma and breast cancer. The median time from the start of chemotherapy to febrile neutropenia
was shorter in the mortality group than the survival group (8.5 days vs. 11 days; p¼ 0.046). The rate of
positive blood cultures was much higher in those who died compared to those who survived (75% vs.
23%, p¼ 0.0001). Gram-negative bacilli were the predominant pathogens in these neutropenic patients,
which is different from the trend in Western countries. Infection with Escherichia coli was more common
in the survival group and Pseudomonas species were more common in the non-survival group. Gram-
positive cocci occurred in similar proportions in both groups. E coli in patients with febrile neu-
tropenia were still susceptible to all ﬁrst-line antibiotics.
Conclusions: Adult cancer patients with febrile neutropenia are at a high risk of mortality, especially those
with documented bacteremia and short times between chemotherapy and neutropenia. Gram-negative
bacilli are still the predominant pathogens in patients with febrile neutropenia and most are still
susceptible to all ﬁrst-line antibiotics. Further investigation into the relationship between the patterns of
different pathogens and mortality in this population is needed.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Febrile neutropenia remains a common complication among
patients with hematological diseases and solid cancers undergoing
various cytotoxic therapies. Despite major improvements in anti-
biotics, febrile neutropenia is associated with substantial morbidity,d Hematology, Buddhist Tzu
, Feng-Xing Road, Tanzi Dist,
4 36065928.
Huang).
ddhist Compassion Relief Tzu Chimortality and costs. The principles that guide the management of
these patients include identiﬁcation of the source of infection and
effective antibiotic treatment. Empirical antibiotic therapy is often
given for broad-spectrum coverage of common pathogens in this
situation [1,2]. Treatment often needs to be tailored to individual
patients once the cause and antibiotic susceptibility pattern of the
isolated organism are known. Over the past three decades, there has
been a considerable change in the epidemiology of pathogens
causing bacteremia in patients with febrile neutropenia. In the
1970s, Gram-negative bacilli caused 60e70% of bacteremia in neu-
tropenic patients [3e5]; in the 1990s, the majority of cases of
bacteremiawere due to Gram-positive cocci. In several large studiesFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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bacteremia dropped approximately from 70% to 30% [3e7]. This
trendmay be attributed to many factors, such as thewidespread use
of prophylactic quinolones [8], the use of long-term indwelling
intravascular catheters and an increased incidence of severe
mucositis as a result of dose-intense chemotherapy.
The microbiological pattern in cancer patients with febrile
neutropenia in Taiwan is different from that in Western countries.
In medical centers in Taiwan, Gram-negative bacteria still account
for most isolated pathogens, followed by Gram-positive bacteria,
fungi and anaerobes [9e13]. Although bacteremia in cancer
patients is not uncommonly reported in Taiwan, little is known
about the differences in bacterial pathogens and antibiotic
susceptibilities in cancer patients who survive or die during febrile
neutropenia. The epidemiology of pathogens is dynamic, so it is
important to have local data when making therapeutic decisions,
especially in cancer patients. In this study, we investigated the
pattern of bacteremic pathogens in adult cancer patients who
survived or died with febrile neutropenia after chemotherapy in
one hospital in eastern Taiwan.
2. Materials and methods
We retrospectively analyzed all adult cancer patients (>18
years) with febrile neutropenia who were admitted to the hema-
tology and oncology wards in our hospital from July 1, 2006 to July
31, 2007. The inclusion criteria were as follows: (1) fever, deﬁned as
a single oral temperature of 38.3 C or an oral temperature of 38 C
lasting 1 hour; and (2) neutropenia, deﬁned as a neutrophil count of
<500 cells/mm3, or a count of <1000 cells/mm3 with a predicted
decrease to <500 cells/mm3 within the next 48e72 hours. Each
separate hospital admission for febrile neutropenia was deﬁned as
one episode. Patients who survived the episode of febrile neu-
tropeniawere referred as the “survival group”. Patients who died in
hospital with death being related to the episode of febrile neu-
tropenia were referred as the “mortality group”. The clinical char-
acteristics and data of the survival and mortality groups were
reviewed.
Bacteremia was deﬁned as a blood culture yielding a pathogenic
organism during febrile neutropenia. If the isolate was a potential
skin contaminant (such as coagulase-negative Staphylococcus or
Corynebacterium species), all of the following criteria had to be met
when considering the pathogen: the presence of an intravascular
catheter, initiation of antimicrobial therapy, and at least one
episode of fever, temperature <36 C, chills or hypotension [5].
Microbiological results were obtained from computerized
laboratory reports, which were conﬁrmed by standard culture
protocols in our hospital. Antibiotic susceptibilities were assessed
using the disk diffusion method. The empirical antibiotic regimen
was determined by guidelines from the Infectious Disease Society
of Taiwan and the Hematology Society of Taiwan [14]. Generally,
a broad-spectrum penicillin ( an aminoglycoside), a third- or
fourth-generation cephalosporin ( an aminoglycoside), or a car-
bapenem was given as empirical therapy after blood cultures were
implemented. The antibiotics were modiﬁed according to the
results of blood culture and sensitivity tests. A glycopeptide (van-
comycin or teicoplanin) was added if Gram-positive bacteria or
a skin infection was highly suspected. There was no routine anti-
bacterial or antifungal prophylaxis in these patients before
chemotherapy during the study period.
Continuous variables were compared by the Student t test,
whereas categorical variables were compared by the Chi-square
test. A p value of less than 0.05 was considered a signiﬁcant
difference. This study was approved by the Research Ethics
Committee of our institution (IRB100-29).3. Results
A total of 80 patients were included who had a total of 110
episodes of febrile neutropenia. Themedian agewas 55 years (range
from 19 to 89 years). Thirty-eight patients weremen and 42 patients
were women (the male to female ratio was 1:1.1). The episodes
occurred mainly (93%) after chemotherapy for their underlying
diseases. Thirty-three (30%) episodes occurred in patients diagnosed
with solid cancers and 77 (70%) in patients with hematological
diseases. The most common underlying solid cancer was breast
cancer, followed by lung cancer. The most common underlying
hematological diseasewas acutemyeloid leukemia, followedbynon-
Hodgkin’s lymphoma. The mean nadir of the absolute neutrophil
count during febrile neutropenia was 150/mL, with counts of 152/mL
in the non-survival group and 138/mL in the survival group (Table 1),
which was not statistically signiﬁcantly different (p¼ 0.775).
The chemotherapeutic agents used before the febrile neu-
tropenic episodes are listed in Table 1, and the most common
chemotherapy was an anthracycline-containing regimen (27%). The
survival group contained more patients receiving anthracycline-
based agents than the mortality group (p¼ 0.041).
Blood cultures were drawn in all 110 episodes. Bloodstream
pathogens were recovered in 34 episodes (31%), in which 48
pathogens were isolated. Among these bloodstream isolates, 30
were Gram-negative bacilli (63%), 16 were Gram-positive cocci
(33%) and 2 were fungi (4%); see Table 1. The most common Gram-
negative bacillus was E coli (n¼ 8), followed by Pseudomonas
species (with Pseudomonas aeruginosa being the most common)
and Klebsiella pneumoniae. The most common Gram-positive cocci
were Staphylococcus species, followed by Streptococcus species.
A total of 16 deaths (14%) occurred among the 110 episodes of
febrile neutropenia (Table 1). The median time from the start of
chemotherapy to febrile neutropenia was 8.5 days in the mortality
group and 11 days in the survival group (p¼ 0.046). Central venous
catheters (CVCs) were implanted during 86 episodes (78%) of
febrile neutropenia. The percentage of patients with CVC implants
in the morality group was 63% (n¼ 10) and the percentage in the
survival group was 81% in (n¼ 76). Three-quarters of those who
died had hematological diseases compared to 69% in the survival
group (p¼ 0.637).
The positive blood culture ratewasmuch higher in themortality
group than in the survival group (75% vs. 23%, p¼ 0.0001). Themost
common bacterial species isolated from patients who died were
P aeruginosa and K pneumoniae. This was different from those who
survived, in whom E coli and Staphylococcus epidermidis were
dominant.
The antimicrobial susceptibilities of the major bacterial patho-
gens isolated in patients with febrile neutropenia are shown in
Table 2. Most of the common Gram-negative bacteria were
susceptible to common empirical antibiotics, such as piperacillin/
tazobactam, ceftazidime and the carbapenems, with a response
range of 67% to 100%. The most common Gram-negative bacillus,
E coli, was 100% susceptible to all third-generation cephalosporins,
carbapenems and ﬂuoroquinolones. Most Gram-positive bacteria
were resistant to either penicillin or oxacillin, but almost all were
sensitive to vancomycin (88%) or teicoplanin (100%).4. Discussion
Although bacteremia in cancer patients is not uncommonly re-
ported in Taiwan, little is known about differences in bacterial
pathogens between thosewho survive and thosewho die during an
episode of febrile neutropenia. The mortality rate among our
patients with febrile neutropenia was 14%.
Table 1
Clinical characteristics and bloodstream pathogens isolated in patients who died
(mortality group) or survived (survival group) during febrile neutropenia (FN).
Total number
of episodes of
FN (n¼ 110)
Mortality
group
(n¼ 16)
Survival
group
(n¼ 94)
p
Disease subtypes
Hematological disease (%) 77 12 (75%) 65 (69%) 0.637
Acute leukemia 44 6 38
Lymphoma 17 3 14
Myeloma 9 2 7
Myelodysplasia 1 1 d
Othersa 6 d 6
Solid cancer (%) 33 4 (25%) 29 (31%)
Colorectal cancer 2 2 d
Breast cancer 12 d 12
Lung cancer 9 d 9
Head and neck cancer 4 d 4
Esophageal cancer 1 1 d
Othersa 5 1 4
Chemotherapy regimen
Alkylator-containing 22 1 21 0.137
Platinum-containing 21 4 17 0.515
Anthracycline-containing 30 1 29 0.041
Taxane-containing 11 0 11 0.149
Other agentsb 26 5 21 0.438
Number with bacteremia,
(% of FN episodes)
34 (31%) 12 (75%) 22 (23%) 0.0001
Median time to FN after
chemotherapy (d)
11 8.5 11 0.046
Central venous catheter 86 (78%) 10 (63%) 76 (81%) 0.10
Mean absolute neutrophil
counts
150 138 152 0.775
Total number where
pathogens were isolated
48 16 32
Gram-positive cocci 16 (33%) 5 (31%) 11 (34%) 0.91
Staphylococcus 8 2 6
Streptococcus 4 3 1
Enterococcus 1 d 1
Othersc 3 d 3
Gram-negative bacilli 30 (63%) 9 (56%) 21 (66%) 0.75
E coli 8 1 7
Pseudomonas spp. 6 4 2
K pneumonia 6 2 4
A baumanii 3 1 2
Othersd 7 1 6
Fungus 2 (4%) 2 (13%) 0
a Other regimens include regimens without alkylator, anthracycline, platinum
and taxane.
b Other hematological diseases include chronic leukemia (n¼ 1) and aplastic
anemia (n¼ 5). Other solid cancers include primary peritoneal carcinoma, neuro-
endocrine carcinoma and metastatic carcinoma of unknown origin.
c Other Gram-positive cocci include Enterococci cloacae and Corynebacterium.
d Other Gram-negative bacilli include Proteus mirabilis, Stenotrophomonas mal-
tophilia, Vibrio parahaemolyticus, Aeromonas sobria, Alcaligenes faecalis and Chrys-
eobacterium indologenes.
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patients with febrile neutropenia, such as uncontrolled infection,
underlying malignant diseases, intensive cytotoxic agents and the
functional reserve of the bone marrow [3].Table 2
In vitro antimicrobial susceptibility of bacteria isolated in patients with febrile neutropen
Bacteria Percentage of total num
Piperacillin/Tazobactam Ceftazidime L
Staphylococcus (n¼ 8)
Streptococcus (n¼ 4)
E coli (n¼ 8) 100% 100% 1
Pseudomonas spp. (n¼ 6) 100% 83% N
Klebsiella pneumoniae (n¼ 6) 83% 83% 6
Acinetobacter baumanii (n¼ 3) 67% 67% 3In our study, the positive blood culture rate was much higher in
the mortality group than the survival group (75% vs. 23%,
p¼ 0.0001). Although bacteremia accounts for only about one-third
of infections among cancer patients with febrile neutropenia, it is
reasonable to assume that there is a higher risk of mortality in
cancer patients with than those without bacteremia [15].
Our data also showed that the average time from chemotherapy
to neutropenia was shorter in those who died compared to those
who survived (8.5 days vs. 11 days, p ¼ 0.046). This phenomenon
may indicate the different susceptibilities of the patients in the
former group to fatal infection. Different chemotherapy agents
might inﬂuence the duration of neutropenia and time to
neutropenia. More patients in the survival group received
anthracycline-based agents compared with those who died, but
there were no differences between other regimens, such as plat-
inum- or taxane-based chemotherapy. Although limited by bias
from the small sample size and the heterogeneity of the different
regimens, there was a difference between patients receiving
anthracycline-based regimens and those receiving other agents
(p¼ 0.041). Conﬁrmation of the different mechanisms by which
cytotoxic drugs work and their impact on patients with febrile
neutropenia requires further study.
The shift of balance of predominant pathogens in Western
countries was not seen in our study. Gram-negative bacilli
remained the dominant pathogens in our institution, comprising
63% of isolates from adults with febrile neutropenia. This
percentage is similar to data from other medical centers in Taiwan
[9e13]. In Kuderer’s study [15], Gram-negative bacteremia was
a risk factor for inpatient mortality in neutropenic patients.
Although the culture rate of Gram-negative bacilli was similar in
the groups in our study, the pathogens were somewhat different
between groups. P aeruginosa and K penumoniae were the most
common pathogens in the mortality group. In contrast, E coli was
the most common pathogen in the patients who survived and
occurred most frequently in patients with hematological malig-
nancies, especially acute leukemia and lymphoma.
Different pathogens found between the groups might also have
inﬂuenced the patients’ survival. P aeruginosa and K penumoniae
are less susceptible to common ﬁrst-line antibiotics than E coli in
our hospital. The strains of E coli were all susceptible to almost all
ﬁrst-line antibiotics used in febrile neutropenia. The antibiotic
susceptibility of different pathogens may be an explanation for the
differences in survival among cancer patients with febrile neu-
tropenia, but clariﬁcation of the relationship between different
bacterial virulence and survival in cancer patients requires further
microbiological or molecular study.
The percentage of Gram-positive bacteremia in our cancer
patients with febrile neutropenia was 33%. Most of the cancer
patients needed CVC for the administration of intravenous chemo-
therapy. The percentage of CVC implants and Gram-positive bacter-
emia were similar in the two groups (p¼ 0.10). Although a CVC is
known to be an important risk factor for infection with Gram-
positive bacteremia, the exact relationship between CVC implants
and the survival of febrile neutropenic patients is still unknown.ia.
ber of isolates from febrile neutropenia susceptible to
evoﬂoxacin Imipenam Meropenam Amikacin Vancomycin
88%
100%
00% 100% 100% 100% NA
A 83% 83% 100% NA
7% 83% 83% 83% NA
3% 67% 67% 67% NA
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and Gram-negative bacilli to available treatments. The Gram-
positive cocci were all resistant to either penicillin or oxacillin,
but were susceptible to vancomycin and teicoplanin. Although
E coli resistance to ﬂuoroquinolones is an emerging problem in
Taiwan and Western countries [16e18], we did not ﬁnd this
phenomenon in our study population. The fact that the E coli
isolates in our study were susceptible to almost all ﬁrst-line anti-
biotics suggests that the application of antibiotics in this institution
is still under reasonable control. Resistance to ﬁrst-line antibiotics
often emerges from extensive antibiotic treatment or prophylaxis.
We did not routinely use prophylactic ﬂuoroquinolone in these
neutropenic patients, and this may explain the susceptibility of
E coli. The number of cases for each species was small, however, and
therefore the susceptibility rate might have been underestimated
in this study. Further conﬁrmation with a larger population is
needed.
In addition to the intrinsic virulence of bacteria, the immuno-
logical competence of the host plays an important role in infection
in cancer patients. Hematological malignancies, especially acute
leukemia or lymphoma, often reﬂect the impaired marrow
reserves and the need for more intensive chemotherapy than solid
cancers. This accounts for the high mortality risk in febrile neu-
tropenic patients. Infection in patients with various hematological
malignancies were not statistically signiﬁcantly different between
the groups (p¼ 0.637), which is probably due to the small sample
size. In the survival group, six episodes were categorized as
“Others,” which included chronic lymphocytic leukemia (n¼ 1)
and aplastic anemia (n¼ 5). These two hematological diseases
have more indolent clinical courses than acute leukemia and
aggressive lymphoma. Patients with these indolent diseases did
not appear in the non-survival group. The impact of different
hematological malignancies and diseases on patients with febrile
neutropenia is an interesting subject and further study is
warranted.5. Conclusions
Adult cancer patients with febrile neutropenia are at a high risk
of mortality, especially those with documented bacteremia and
a short time between chemotherapy and neutropenia. Gram-
negative bacilli are still the predominant pathogens in patients
with febrile neutropenia. The strains of E coli are still susceptible to
all ﬁrst-line antibiotics. Our study provides preliminary local data
on cancer patients treated in eastern Taiwan. The relationships
between different patterns of pathogens and mortality in patients
with febrile neutropenia require further investigation in a larger
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